Statin News and Research RSS Feed - Statin News and Research

Statins are drugs used to lower cholesterol. Your body needs some cholesterol to work properly. But if you have too much in your blood, it can stick to the walls of your arteries, narrowing or even blocking them.
Hospital bed positioning can affect outcomes of stroke patients

Hospital bed positioning can affect outcomes of stroke patients

During the first 24 hours after a stroke, attention to detail --such as hospital bed positioning -- is critical to patient outcomes. [More]
Patient's gene profile influences effects of statins

Patient's gene profile influences effects of statins

The Montreal Heart Institute Research Centre is once again pushing the limits of knowledge in personalized medicine. A meta-analysis combining the results of several pharmacogenomic studies and involving over 40,000 research subjects now makes it possible to demonstrate a different response to statins according to the patient's gene profile. [More]
Research roundup: Home health nurses' workloads; readmissions at the VA; SHOP choices

Research roundup: Home health nurses' workloads; readmissions at the VA; SHOP choices

In anticipation of next year's premium announcements and given some information already made public, concerns have surfaced about the potential for double-digit percent increases in nongroup and small-group health insurance premiums. This analysis shows that, although average annual increases in small-group premiums over the past 13 years averaged roughly 5.5 percent, double-digit average premium increases are common for states and large metropolitan areas. [More]
Rosuvastatin drug more effective among prediabetic patients, finds new study

Rosuvastatin drug more effective among prediabetic patients, finds new study

Cardiovascular disease is the leading causes of death worldwide and high cholesterol plays a major role in accelerating its progression. Medical practitioners have turned to statins as a treatment to decrease cholesterol-carrying lipoproteins such as small dense lipoproteins (sdLDL), considered to be especially harmful. [More]
Rosuvastatin promotes bone growth in mice with achondroplasia symptoms

Rosuvastatin promotes bone growth in mice with achondroplasia symptoms

Skeletal dysplasia is a group of rare diseases that afflict skeletal growth through abnormalities in bone and cartilage. Its onset hits at the fetal stage and is caused by genetic mutations. [More]
‘Reassuring’ findings on microvascular risk in diabetic statin users

‘Reassuring’ findings on microvascular risk in diabetic statin users

Statin treatment prior to diabetes onset does not appear to increase the risk of microvascular disease and may even be protective against some forms, findings from a registry study suggest. [More]
New report outlines cholesterol-targeted approach to treat people at risk for cardiovascular disease

New report outlines cholesterol-targeted approach to treat people at risk for cardiovascular disease

A recent guideline for using statins to reduce atherosclerotic cardiovascular disease has wavered too far from the simple cholesterol goals that have saved thousands of lives in the past decade, and doesn't adequately treat patients as individuals, experts said today in a national report. [More]
People with diabetes may have six-fold higher risk of developing heart failure

People with diabetes may have six-fold higher risk of developing heart failure

People with diabetes who appear otherwise healthy may have a six-fold higher risk of developing heart failure regardless of their cholesterol levels, new Johns Hopkins Bloomberg School of Public Health research suggests. [More]
Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

Wake Forest Baptist Medical Center has been awarded $4.4 million to conduct a multiple-site clinical trial testing the effectiveness of a statin drug in preventing cardiovascular events in women treated for breast cancer. [More]
Researchers uncover intriguing link between heart attacks and protein

Researchers uncover intriguing link between heart attacks and protein

A team of researchers at the University of Ottawa Heart Institute, led by Dr. Alexandre Stewart, have uncovered an intriguing link between heart attacks and a protein that is of great interest to drug companies for its impact on cholesterol. [More]
Alirocumab drug significantly improves cholesterol levels compared to ezetimibe

Alirocumab drug significantly improves cholesterol levels compared to ezetimibe

The investigational drug alirocumab significantly improved cholesterol levels compared to ezetimibe, when added to regular statin therapy in patients with high cholesterol and elevated risk of cardiovascular disease (CVD), according to the ODYSSEY COMBO II trial, presented as a Hot Line today at ESC Congress 2014. [More]
Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol. [More]
Risk-based treatment approach should be considered for patients with hypertension

Risk-based treatment approach should be considered for patients with hypertension

Blood pressure-lowering treatment should target patients at greatest cardiovascular risk and not just those with the highest baseline levels, suggest findings of a meta-analysis. [More]
New guidelines can improve the way statin drugs prescribed to patients at cardiovascular risk

New guidelines can improve the way statin drugs prescribed to patients at cardiovascular risk

New national guidelines can improve the way statin drugs are prescribed to patients at risk for cardiovascular disease, a Yale University study has found. [More]
Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that details from four pivotal trials in the alirocumab ODYSSEY clinical program will be presented on Sunday, August 31, during a Hot Line session at ESC Congress 2014 in Barcelona, Spain, the world's largest cardiology meeting. [More]

New cholesterol guidelines can significantly help reduce cardiovascular events

A study from UT-Southwestern researchers found that recently introduced cholesterol guidelines would significantly reduce new cardiovascular events, when compared to treatment based on previous cholesterol guidelines. [More]
New joint ESC/ESA Guidelines on non-cardiac surgery

New joint ESC/ESA Guidelines on non-cardiac surgery

The publication of the new joint ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management introduces a number of recommendations in the field. Among other topics, the Guidelines include updated information on the use of clinical indices and biomarkers in risk assessment, and the use of novel anticoagulants, statins, aspirin and beta-blockers in risk mitigation. [More]
Findings underscore the importance of prenatal health care, postnatal breastfeeding

Findings underscore the importance of prenatal health care, postnatal breastfeeding

Young adults who were breastfed for three months or more as babies have a significantly lower risk of chronic inflammation associated with cardiovascular and metabolic diseases, according to research from the Brown School at Washington University in St. Louis. [More]
Statin therapy may speed up wound healing following cardiac surgery

Statin therapy may speed up wound healing following cardiac surgery

Statin therapy may help to improve wound healing in patients following cardiac surgery and reduce overall recovery time, especially in patients who are prone to healing complications, according to a review article in the August 2014 issue of The Annals of Thoracic Surgery. [More]
CardioNova initiates Phase 1b clinical trial with AtheroNova's AHRO-001

CardioNova initiates Phase 1b clinical trial with AtheroNova's AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001. [More]